Howard H. Bailey, MD close
Howard H. Bailey, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Howard H. Bailey, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Bailey is the Director of the University of Wisconsin Carbone Cancer Center and a professor of Medicine at the UW School of Medicine and Public Health. Dr. Bailey's clinical expertise is in sarcomas and gynecologic malignancies and his research focus is in anti-cancer drug development, especially chemoprevention, and research network development. He graduated from medical school at the University of North Dakota and completed his internship and residency at Southwestern Michigan Area Health Education Center in Kalamazoo. He completed a fellowship in Medical Oncology at the University of Wisconsin and completed a Research Fellowship at the UW Carbone Cancer Center. Dr. Bailey is board certified in Internal Medicine and Medical Oncology.


Dr. Bailey is the principal investigator of the UW Chemoprevention Consortium, an NCI-sponsored research network of Universities that conduct Phase I and II clinical trials for chemopreventive agents. Dr. Bailey also leads the UWCCC Chemoprevention Scientific Program and Chemoprevention Disease Orientated Work Group. He is the senior leader and advisory committee chair for the Wisconsin Network for Health Research, a collaborative effort across the state to promote greater inter-institutional cooperation in research and to move research results to the bedside more efficiently and effectively. Dr. Bailey was appointed to the national committee which reviews all NCI-designated Cancer Centers in 2011.


Dr. Bailey is the University's expert on drug and nutrient development for the prevention or treatment of cancer and a national expert on chemoprevention. Cancer chemoprevention is the use of natural, synthetic (made in a laboratory) or biologic (form a living source) substances to reverse, suppress or prevent the development of cancer. He is internationally recognized as an expert in chemoprevention and sarcoma and has lectured both in the United States and abroad. Dr. Bailey has directed or participated in more than 100 cancer clinical trials examining agents for prevention or treatment of cancer.



UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Internal Medicine
Medical Oncology
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency Southwestern Michigan Area Health Education Center, Kalamazoo, MI
Internship Southwestern Michigan Area Health Education Center, Kalamazoo, MI
Medical School University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Bailey is involved in the research of new clinical agents for the prevention and treatment of cancer. He leads the Etiology and Chemoprevention Program of the UW Carbone Cancer Center - which examines the causes of cancer and then translates this knowledge to develop and evaluate drugs, vitamins, or other agents to try to reduce the risk of or delay the development of cancer. He is the principal investigator of the Chemoprevention Consortium - a consortium of five national institutions to conduct multiple Phase I and II clinical trials for chemopreventive agents.

PubMed Articles
Joseph JV Brasacchio R Fung C Reeder J Bylund K Sahasrabudhe D Yeh SY Ghazi A Fultz P Rubens D Wu G Singer E Schwarz E Mohile S Mohler J Theodorescu D Lee YF Okunieff P McConkey D Rashid H Chang C Fradet Y Guru K Kukreja J Sufrin G Lotan Y Bailey H Noyes K Schwartz S Rideout K Bratslavsky G Campbell SC Derweesh I Abrahamsson PA Soloway M Gomella L Golijanin D Svatek R Frye T Lerner S Palapattu G Wilding G Droller M Trump D A Festschrift in Honor of Edward M. Messing, MD, FACS. Bladder Cancer . 2018 Oct 3;4(Suppl 1):S1-S43
[PubMed ID: 30443561]
Mak LY Cruz-Ramón V Chinchilla-López P Torres HA LoConte NK Rice JP Foxhall LE Sturgis EM Merrill JK Bailey HH Méndez-Sánchez N Yuen MF Hwang JP Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book . 2018 May 23;38:262-279
[PubMed ID: 30231359]
Kyriakopoulos CE Braden AM Kolesar JM Eickhoff JC Bailey HH Heideman J Liu G Wisinski KB A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Invest New Drugs . 2017 Jun;35(3):290-297
[PubMed ID: 28004284]
Gee JR Saltzstein DR Kim K Kolesar J Huang W Havighurst TC Wollmer BW Stublaski J Downs T Mukhtar H House MG Parnes HL Bailey HH A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers. Cancer Prev Res (Phila) . 2017 May;10(5):298-307
[PubMed ID: 28325826]
Jarrard D Konety B Huang W Downs T Kolesar J Kim KM Havighurst T Slaton J House MG Parnes HL Bailey HH Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D<sub>3</sub>) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy. Am J Clin Exp Urol . 2016;4(2):17-27
[PubMed ID: 27766277]
Gee JR Saltzstein DR Messing E Kim K Kolesar J Huang W Havighurst TC Harris L Wollmer BW Jarrard D House M Parnes H Bailey HH Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy. Eur J Cancer Prev . 2016 Jul;25(4):312-20
[PubMed ID: 26313229]
Bailey HH Chuang LT duPont NC Eng C Foxhall LE Merrill JK Wollins DS Blanke CD American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. J Clin Oncol . 2016 May 20;34(15):1803-12
[PubMed ID: 27069078]
Fabian CJ Kimler BF Zalles CM Phillips TA Metheny T Petroff BK Havighurst TC Kim K Bailey HH Heckman-Stoddard BM Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer. Cancer Prev Res (Phila) . 2015 Dec;8(12):1146-55
[PubMed ID: 26391916]
Wisinski KB Ledesma WM Kolesar J Wilding G Liu G Douglas J Traynor AM Albertini M Mulkerin D Bailey HH A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract . 2015 Dec;21(6):416-24
[PubMed ID: 24986793]
Anderson CP Matthay KK Perentesis JP Neglia JP Bailey HH Villablanca JG Groshen S Hasenauer B Maris JM Seeger RC Reynolds CP Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma. Pediatr Blood Cancer . 2015 Oct;62(10):1739-46
[PubMed ID: 26153194]
Kolesar JM Pomplun M Havighurst T Stublaski J Wollmer B Kim K Tangrea JA Parnes HL House MG Gee J Messing E Bailey HH Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract . 2015 Apr;21(2):128-31
[PubMed ID: 24642450]
Masters GA Krilov L Bailey HH Brose MS Burstein H Diller LR Dizon DS Fine HA Kalemkerian GP Moasser M Neuss MN O'Day SJ Odenike O Ryan CJ Schilsky RL Schwartz GK Venook AP Wong SL Patel JD Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol . 2015 Mar 1;33(7):786-809
[PubMed ID: 25605863]
Agger WA Siddiqui D Lovrich SD Callister SM Borgert AJ Merkitch KW Mason TC Baumgardner DJ Burmester JK Shukla SK Welter JD Stewart KS Washburn MJ Bailey HH Epidemiologic factors and urogenital infections associated with preterm birth in a midwestern U.S. population. Obstet Gynecol . 2014 Nov;124(5):969-77
[PubMed ID: 25437726]
Adhami VM Bailey HH Mukhtar H Cancer chemoprevention is not a failure. Carcinogenesis . 2014 Sep;35(9):2154-5
[PubMed ID: 24970761]
Deming DA Ninan J Bailey HH Kolesar JM Eickhoff J Reid JM Ames MM McGovern RM Alberti D Marnocha R Espinoza-Delgado I Wright J Wilding G Schelman WR A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Invest New Drugs . 2014 Apr;32(2):323-9
[PubMed ID: 24114123]
Schelman WR Traynor AM Holen KD Kolesar JM Attia S Hoang T Eickhoff J Jiang Z Alberti D Marnocha R Reid JM Ames MM McGovern RM Espinoza-Delgado I Wright JJ Wilding G Bailey HH A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Invest New Drugs . 2013 Dec;31(6):1539-46
[PubMed ID: 24114121]
Kolesar JM Traynor AM Holen KD Hoang T Seo S Kim K Alberti D Espinoza-Delgado I Wright JJ Wilding G Bailey HH Schelman WR Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer Chemother Pharmacol . 2013 Sep;72(3):661-7
[PubMed ID: 23903894]
Wisinski KB Faerber A Wagner S Havighurst TC McElroy JA Kim K Bailey HH Predictors of willingness to participate in window-of-opportunity breast trials. Clin Med Res . 2013 Sep;11(3):107-12
[PubMed ID: 23580787]
Gee J Bailey H Kim K Kolesar J Havighurst T Tutsch KD See W Cohen MB Street N Levan L Jarrard D Wilding G Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate . 2013 Jun;73(9):970-8
[PubMed ID: 23335089]
Bailey HH Mukhtar H Green tea polyphenols and cancer chemoprevention of genitourinary cancer. Am Soc Clin Oncol Educ Book . 2013;:92-6
[PubMed ID: 23714466]